Related Experiment Videos
Acute lymphocytic leukemia (ALL) in elderly patients
J F Virgilio1, L C Moscinski, O F Ballester
1Leukemia/Lymphoma Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Hematological Oncology
|May 1, 1993
Summary
Elderly patients with acute lymphoblastic leukemia (ALL) have poorer outcomes, with lower remission rates and shorter survival compared to younger adults. This highlights the need for tailored treatments for older ALL patients.
Area of Science:
- Hematology
- Oncology
- Geriatric Medicine
Background:
- Acute lymphoblastic leukemia (ALL) affects adults, with outcomes varying by age.
- Understanding age-related differences in ALL is crucial for optimizing treatment.
Purpose of the Study:
- To compare clinical and biologic characteristics.
- To evaluate response to therapy and outcomes in adult ALL patients aged 55 and older versus those younger than 55.
Main Methods:
- Retrospective review of clinical and laboratory data.
- Analysis of 33 newly diagnosed adult ALL patients over a nine-year period.
- Data collected from a University-affiliated Cancer Center and a Veteran's Hospital.
Main Results:
- No significant differences in prognostic indicators like cytogenetic abnormalities or immunophenotype were observed between age groups.
- Patients over 55 experienced significantly lower remission rates.
- Adults over 55 had significantly shorter survival durations compared to younger patients.
Conclusions:
- The prognosis for elderly patients with ALL is poor.
- Higher early induction death rates and increased disease refractoriness to standard chemotherapy contribute to poor outcomes in older adults.
- Novel treatment protocols and a deeper understanding of the unique biology of ALL in the elderly are necessary.